The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISAL 2019 | Len/aza seems effective as a novel salvage therapy for post-transplant relapsed AML: VIOLA results
The VIOLA trial (ISCRCTN98163167; EudraCT 2013-002118-11), part of the Bloodwise Trials Acceleration Program, investigated the combination of lenalidomide and azacitidine as a novel salvage therapy for acute myeloid leukemia (AML) patients who have relapsed after allogeneic stem cell transplantation. We spoke to Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, of the University of Birmingham, Birmingham, UK, about the promising recently published results. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.
